Zelira Therapeutics Ltd - Asset Resilience Ratio

Latest as of December 2020: 20.17%

Zelira Therapeutics Ltd (ZLD) has an Asset Resilience Ratio of 20.17% as of December 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ZLD strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

AU$8.64 Million

≈ $6.11 Million USD Cash + Short-term Investments

Total Assets

AU$42.85 Million

≈ $30.32 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2006–2021)

This chart shows how Zelira Therapeutics Ltd's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Zelira Therapeutics Ltd to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Zelira Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ZLD stock market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$8.64 Million	20.17%
Short-term Investments	AU$0.00	0%
Total Liquid Assets	AU$8.64 Million	20.17%

Asset Resilience Insights

Good Liquidity Position: Zelira Therapeutics Ltd maintains a healthy 20.17% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Zelira Therapeutics Ltd Industry Peers by Asset Resilience Ratio

Compare Zelira Therapeutics Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Revolution Medicines Inc NASDAQ:RVMD	Biotechnology	65.10%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Hugel Inc KQ:145020	Biotechnology	29.57%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	Biotechnology	39.07%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A SHG:688076	Biotechnology	2.30%
Absci Corp NASDAQ:ABSI	Biotechnology	59.86%
Shenzhen Weiguang Biological Products Co Ltd SHE:002880	Biotechnology	5.52%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%

Annual Asset Resilience Ratio for Zelira Therapeutics Ltd (2006–2021)

The table below shows the annual Asset Resilience Ratio data for Zelira Therapeutics Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2021-06-30	-0.25%	AU$-99.85K ≈ $-70.65K	AU$39.37 Million ≈ $27.85 Million	+0.05pp
2020-06-30	-0.30%	AU$-108.22K ≈ $-76.57K	AU$35.79 Million ≈ $25.32 Million	-87.73pp
2019-06-30	87.42%	AU$3.07 Million ≈ $2.17 Million	AU$3.52 Million ≈ $2.49 Million	-2.63pp
2018-06-30	90.05%	AU$5.69 Million ≈ $4.02 Million	AU$6.31 Million ≈ $4.47 Million	-8.70pp
2017-06-30	98.75%	AU$7.87 Million ≈ $5.57 Million	AU$7.97 Million ≈ $5.64 Million	+81.30pp
2009-06-30	17.46%	AU$619.26K ≈ $438.17K	AU$3.55 Million ≈ $2.51 Million	-2.86pp
2006-06-30	20.32%	AU$5.37 Million ≈ $3.80 Million	AU$26.45 Million ≈ $18.72 Million	--

pp = percentage points

About Zelira Therapeutics Ltd

AU:ZLD Australia Biotechnology

Market Cap

$4.21 Million

AU$5.95 Million AUD

Market Cap Rank

#28885 Global

#1598 in Australia

Share Price

AU$0.50

Change (1 day)

+0.00%

52-Week Range

AU$0.31 - AU$0.91

All Time High

AU$26.25